Strategic Partnership in the Medical Device Sector
First written in FY2016. 5 of 12 entries say "Advanced", first in FY2024. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「The company entered into an exclusive global distribution agreement with EndoRobotics Co., Ltd., which is developing solutions for endoscopic treatment using robotic technology.」
In addition to investing in Swan EndoSurgical, the company entered into an exclusive global distribution agreement with EndoRobotics for endoscopic treatment robots. - 2026-05-12AdvancedRevision of earnings forecasts
「As one option for realizing endoluminal robots, our Group will invest jointly with Revival Healthcare Capital in Swan EndoSurgical and aims to develop new endoluminal robotic products.」
Specifies the purpose of the investment in the jointly controlled company with a fund affiliated with Revival Healthcare Capital and the aim of developing endoluminal robotic products. - FY2026-H1AdvancedAnnual report
「At a meeting of the Board of Directors held on 25 July 2025, the company resolved to establish Swan EndoSurgical, Inc., a joint venture with RVLHC SE Holdings, LLC, a fund managed by Revival Healthcare Capital, an investment firm specialising in the medical technology sector, and to invest in the joint venture through its consolidated subsidiary Olympus Corporation of the Americas. The company made the investment on the same day.」
As part of its strategic partnerships in the medical device field, the company established a joint venture with a Revival Healthcare Capital-affiliated fund to develop endoluminal robots and made the investment on 25 July 2025. - FY2025AdvancedAnnual report
「The company is also developing cloud-based endoscopy systems in cooperation with NTT, including real-time remote diagnosis and treatment.」
Under its strategic partnerships, the company advanced collaboration with NTT through the development of cloud-based endoscopy systems aimed at enabling remote diagnosis and treatment. - FY2024AdvancedAnnual report
「The company is also advancing product development by strengthening its collaboration with Sony Corporation on next-generation endoscopy systems and promoting collaboration with Canon Medical Systems Corporation on ultrasound endoscopy systems.」
After transitioning its comprehensive partnership with TERUMO CORPORATION to individual agreements, the company strengthened its collaboration with Sony on next-generation endoscopy systems and began and promoted collaboration with Canon Medical Systems on ultrasound endoscopy systems. - FY2024-Q3ReframedAnnual report
「The company and TERUMO CORPORATION agreed on 30 October 2023 to transition the above partnership agreement to individual agreements.」
While transitioning its former comprehensive medical device development and sales partnership with TERUMO CORPORATION to individual agreements, the company entered into an agreement with Sony and Sony Olympus Medical Solutions to collaborate on the development of next-generation endoscopy system products. - FY2024-Q2ReframedAnnual report
「On 4 August 2023, the group acquired all shares of OTB, making OTB a wholly owned subsidiary of the group. The company and TERUMO CORPORATION also agreed on 30 October 2023 to transition the above partnership agreement to individual agreements.」
The company confirmed that OTB, formerly a joint venture with TERUMO CORPORATION, had become a wholly owned subsidiary, and changed the relationship by transitioning the former comprehensive partnership agreement to individual agreements. - FY2024-Q1ReframedAnnual report
「On 24 July 2023, the company agreed to acquire all shares of its consolidated subsidiary Olympus Terumo Biomaterials Corporation through its group, and on 4 August 2023, the group acquired all shares of OTB. As a result of this acquisition, OTB became a wholly owned subsidiary of the group.」
The relationship with OTB, a joint venture with TERUMO CORPORATION, changed through the additional acquisition of 33.4% of its shares, making it a wholly owned subsidiary of the group. - FY2020RestatedAnnual report
「At a meeting of the Board of Directors held on 7 November 2019, the company resolved to terminate its capital alliance with Sony Corporation and, on 8 November 2019, entered into a memorandum of understanding regarding the termination of the capital alliance agreement. The business partnership between the company and Sony Corporation will continue.」
The company reconfirmed the scope of its relationship with Sony, under which the capital alliance ended while the business partnership continues. - FY2020-Q3SoftenedAnnual report
「At a meeting of the Board of Directors held on 7 November 2019, the company resolved to terminate its capital alliance with Sony Corporation and, on 8 November 2019, entered into a memorandum of understanding regarding the termination of the capital alliance agreement. The business partnership between the company and Sony Corporation will continue.」
Although the capital alliance agreement with Sony ended, the business partnership will continue, reducing the scope of the partnership. - FY2018RestatedAnnual report
「We are building long-term strategic partnerships with leading companies in the industry in technology and product development. However, if we become unable to maintain these partnerships because of financial or other business issues arising with our strategic partners or changes in objectives, our group's business activities may be disrupted.」
The company reiterated its policy of pursuing strategic partnerships with TERUMO CORPORATION, Sony and others, as well as the risk of being unable to maintain those partnerships. - FY2016First statedAnnual report
「We are building long-term strategic partnerships with leading companies in the industry in technology and product development.」
The company disclosed a medical device development and sales partnership with TERUMO CORPORATION and a medical joint venture and business partnership with Sony.